{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:50:46Z","timestamp":1761519046187},"reference-count":27,"publisher":"Pharmaceutical Society of Japan","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2013]]},"DOI":"10.1248\/bpb.b12-01086","type":"journal-article","created":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T22:47:42Z","timestamp":1359672462000},"page":"676-681","source":"Crossref","is-referenced-by-count":14,"title":["Interindividual Variations in Aprepitant Plasma Pharmacokinetics in Cancer Patients Receiving Cisplatin-Based Chemotherapy for the First Time"],"prefix":"10.1248","volume":"36","author":[{"given":"Shinya","family":"Motohashi","sequence":"first","affiliation":[{"name":"Department of Hospital Pharmacy, Hamamatsu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuaki","family":"Mino","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Hamamatsu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhito","family":"Hori","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Hamamatsu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Naito","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Hamamatsu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Hosokawa","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology\/Head & Neck Surgery, Hamamatsu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Furuse","sequence":"additional","affiliation":[{"name":"Department of Urology, Hamamatsu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichiro","family":"Ozono","sequence":"additional","affiliation":[{"name":"Department of Urology, Hamamatsu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Mineta","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology\/Head & Neck Surgery, Hamamatsu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Hamamatsu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2014The Aprepitant Protocol 052 Study Group. <i>J. Clin. Oncol.<\/i>, 21, 4112\u20134119 (2003)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, Aprepitant Protocol 054 Study Group. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. <i>Cancer<\/i>, 97, 3090\u20133098 (2003).","DOI":"10.1002\/cncr.11433"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.050"},{"key":"4","unstructured":"4) Majumdar AK, Howard L, Goldberg MR, Hickey L, Constanzer M, Rothenberg PL, Crumley TM, Panebianco D, Bradstreet TE, Bergman AJ, Waldman SA, Greenberg HE, Butler K, Knops A, De Lepeleire I, Michiels N, Petty KJ. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. <i>J. Clin. Pharmacol.<\/i>, 46, 291\u2013300 (2006)."},{"key":"5","unstructured":"5) Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K, Chen C, Thompson K, Higgins R, Batra U, Shelukar S, Kwei G, Storey D. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. <i>Int. J. Pharm.<\/i>, 285, 135\u2013146 (2004)."},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(96)00020-2"},{"key":"7","unstructured":"7) Huskey SE, Dean BJ, Bakhtiar R, Sanchez RI, Tattersall FD, Rycroft W, Hargreaves R, Watt AP, Chicchi GG, Keohane C, Hora DF, Chiu SH. Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets. <i>Drug Metab. Dispos.<\/i>, 31, 785\u2013791 (2003)."},{"key":"8","unstructured":"8) Bergstr\u00f6m M, Hargreaves RJ, Burns HD, Goldberg MR, Sciberras D, Reines SA, Petty KJ, Ogren M, Antoni G, L\u00e5ngstr\u00f6m B, Eskola O, Scheinin M, Solin O, Majumdar AK, Constanzer ML, Battisti WP, Bradstreet TE, Gargano C, Hietala J. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. <i>Biol. Psychiatry<\/i>, 55, 1007\u20131012 (2004)."},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.62"},{"key":"10","unstructured":"10) Nakade S, Ohno T, Kitagawa J, Hashimoto Y, Katayama M, Awata H, Kodama Y, Miyata Y. Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. <i>Cancer Chemother. Pharmacol.<\/i>, 63, 75\u201383 (2008)."},{"key":"11","unstructured":"11) Huskey SE, Dean BJ, Doss GA, Wang Z, Hop CE, Anari R, Finke PE, Robichaud AJ, Zhang M, Wang B, Strauss JR, Cunningham PK, Feeney WP, Franklin RB, Baillie TA, Chiu SH. The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs. <i>Drug Metab. Dispos.<\/i>, 32, 246\u2013258 (2004)."},{"key":"12","unstructured":"12) Sanchez RI, Wang RW, Newton DJ, Bakhtiar R, Lu P, Chiu SH, Evans DC, Huskey SE. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. <i>Drug Metab. Dispos.<\/i>, 32, 1287\u20131292 (2004)."},{"key":"13","unstructured":"13) Chavez-Eng CM, Constanzer ML, Matuszewski BK. Simultaneous determination of Aprepitant and two metabolites in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection. <i>J. Pharm. Biomed. Anal.<\/i>, 35, 1213\u20131229 (2004)."},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1038\/86882"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2004.04.017"},{"key":"16","unstructured":"16) U.S. Food and Drug Administration. \u201cGuidance for industry bioanalytical method validation.\u201d: \u2039http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatroyInformation\/Guidances\/UCM070107.pdf\u203a, cited 6 October, 2011."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Fukuen S, Fukuda T, Maune H, Ikenaga Y, Yamamoto I, Inaba T, Azuma J. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. <i>Pharmacogenetics<\/i>, 12, 331\u2013334 (2002).","DOI":"10.1097\/00008571-200206000-00009"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1519-2"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(77)91531-5"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Doi Y, Kubo M, Yonemoto K, Ninomiya T, Iwase M, Tanizaki Y, Shikata K, Iida M, Kiyohara Y. Liver enzymes as a predictor for incident diabetes in a Japanese population: the Hisayama study. <i>Obesity<\/i> (Silver Spring), 15, 1841\u20131850 (2007).","DOI":"10.1038\/oby.2007.218"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. <i>Diabetes Care<\/i>, 28, 2913\u20132918 (2005).","DOI":"10.2337\/diacare.28.12.2913"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Yamada J, Tomiyama H, Yambe M, Koji Y, Motobe K, Shiina K, Yamamoto Y, Yamashina A. Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome. <i>Atherosclerosis<\/i>, 189, 198\u2013205 (2006).","DOI":"10.1016\/j.atherosclerosis.2005.11.036"},{"key":"23","unstructured":"23) Kugelman A, Choy HA, Liu R, Shi MM, Gozal E, Forman HJ. gamma-Glutamyl transpeptidase is increased by oxidative stress in rat alveolar L2 epithelial cells. <i>Am. J. Respir. Cell Mol. Biol.<\/i>, 11, 586\u2013592 (1994)."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Nannipieri M, Gonzales C, Baldi S, Posadas R, Williams K, Haffner SM, Stern MP, Ferrannini E, Mexico City diabetes study. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. <i>Diabetes Care<\/i>, 28, 1757\u20131762 (2005).","DOI":"10.2337\/diacare.28.7.1757"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199834050-00003"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) M\u00fchlberg W, Platt D. Age-dependent changes of the kidneys: pharmacological implications. <i>Gerontology<\/i>, 45, 243\u2013253 (1999).","DOI":"10.1159\/000022097"},{"key":"27","unstructured":"27) Rosso Felipe C, de Sandes TV, Sampaio EL, Park SI, Silva HT Jr, Medina Pestana JO. Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs. <i>Transplant. Proc.<\/i>, 41, 1441\u20131455 (2009)."}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/36\/4\/36_b12-01086\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T05:00:57Z","timestamp":1615870857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/36\/4\/36_b12-01086\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b12-01086","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}